FrancophonIA/ELRC3.0 huggingface dataset:
English: You can also report side effects directly via national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of the medicine.
Croatian: Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
English: 30 pack - 18 months
Croatian: 6.3 Rok valjanosti pakiranje od 5 - 12 mjeseci pakiranje od 30 - 18 mjeseci pakiranje od 90 - 18 mjeseci
English: LUMIGAN 0.3 mg/mL single-dose should only be applied to the eye
Croatian: Jednodozni LUMIGAN 0,3 mg/ml treba primijeniti isključivo u oko.
English: What LUMIGAN 0.1 mg/ml is and what it is used for
Croatian: Što je LUMIGAN 0,1 mg/ml i za što se koristi
English: • Swollen eyelids
Croatian: • Upala šarenice
English: Do not use this medicine after the expiry date which is stated on the single-dose container and the carton after the expiry date (EXP):.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na jednodoznom spremniku i kutiji iza oznake EXP.
English: Liquid is constantly being drained out of the eye and new liquid is made to replace this.
Croatian: Ta tekućina čitavo vrijeme nastaje i istječe iz oka.
English: Most were ocular, mild to moderate, and none were serious.
Croatian: Većina ih je bila na očima, blage do umjerene i niti jedna od njih nije bila ozbiljne prirode.
English: Vascular disorders common hypertension
Croatian: Krvožilni poremećaji često hipertenzija
English: After once daily ocular administration of one drop of LUMIGAN 0.3 mg/ml to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.
Croatian: Nakon što se tijekom dva tjedna jednom dnevno u svako oko primjenjivala po jedna kap otopine LUMIGAN 0,3 mg/ml, koncentracije u krvi dosegle su vrhunac unutar 10 minuta od davanja doze i padale su do razine niže od detekcije (0,025 ng/ml) unutar 1,5 sata nakon primjene.
English: There have been rare spontaneous reports of reactivation of previous corneal infiltrates or ocular infections with bimatoprost 0.3 mg/ml eye drops, solution.
Croatian: Bilo je nekoliko rijetkih spontanih izvješća o ponovnoj aktivaciji prethodnih rožničnih infiltrata ili očnih infekcija s otopinom bimatoprost 0,3 mg/ml kapi za oko.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE JEDNODOZNI SPREMNIK
English: • Shortness of breath
Croatian: • Nedostatak zraka
English: After once daily ocular administration of one drop of 0.3 mg/ml bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.
Croatian: Nakon što se tijekom dva tjedna jednom dnevno u svako oko primjenjivala po jedna kap 0,3 mg/ml bimatoprosta, koncentracije u krvi dosegle su vrhunac unutar 10 minuta od davanja doze i padale su do razine niže od detekcije (0,025 ng/ml) unutar 1,5 sata od primjene.
English: What LUMIGAN 0.1 mg/ml looks like and contents of the pack LUMIGAN is a colourless clear eye drop solution in a pack containing either 1 plastic bottle or 3 plastic bottles each with a screw cap. Each bottle is approximately half full and contains 3 millilitres of solution.
Croatian: Kako LUMIGAN 0,1 mg/ml izgleda i sadržaj pakiranja LUMIGAN kapi za oko su bezbojna, prozirna otopina u pakiranju koje sadrži ili 1 plastičnu bočicu ili 3 plastične bočice svaka sa zatvaračem s navojem.
English: • Itchiness (up to 14% of people)
Croatian: • Svrbež (do 14% ljudi)
English: What LUMIGAN 0.3 mg/ml is and what it is used for
Croatian: Što je LUMIGAN 0,3 mg/ml i za što se koristi
English: OUTER CARTON CONTAINING 30 SINGLE-DOSE CONTAINERS
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA KOJA SADRŽI 30 JEDNODOZNIH SPREMNIKA
English: What LUMIGAN 0.3 mg/ml looks like and contents of the pack LUMIGAN is a colourless clear eye drop solution in a pack containing either 1 plastic bottle or 3 plastic bottles each with a screw cap. Each bottle is approximately half full and contains 3 millilitres of solution.
Croatian: Kako LUMIGAN 0,3 mg/ml izgleda i sadržaj pakiranja LUMIGAN kapi za oko su bezbojna, prozirna otopina u pakiranju koje sadrži ili 1 plastičnu bočicu ili 3 plastične bočice svaka sa zatvaračem s navojem.
English: What you need to know before you use LUMIGAN 0.1 mg/ml
Croatian: Što morate znati prije nego počnete primjenjivati LUMIGAN 0,1 mg/ml
English: In a 3 month clinical study, approximately 29% of patients treated with LUMIGAN 0.3 mg/mL singledose experienced adverse reactions.
Croatian: U 3-mjesečnom kliničkom ispitivanju 29% bolesnika liječenih LUMIGAN 0,3 mg/ml kapima za oko imalo je nuspojave.
English: Eye drops, solution.
Croatian: Kapi za oko, otopina
English: What LUMIGAN 0.1 mg/ml is and what it is used for What you need to know before you use LUMIGAN 0.1 mg/ml How to use LUMIGAN 0.1 mg/ml Possible side effects
Croatian: Što je LUMIGAN 0,1 mg/ml i za što se koristi Što morate znati prije nego počnete primjenjivati LUMIGAN 0,1 mg/ml Kako primjenjivati LUMIGAN 0,1 mg/ml Moguće nuspojave
English: • growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years
Croatian: • pojačan rast trepavica i do 45% u prvoj godini primjene s padom incidencije novih prijava na 7% u drugoj i 2% u trećoj godini primjene.
English: - The other ingredients are benzalkonium chloride (preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water.
Croatian: - Drugi sastojci su benzalkonijev klorid (konzervans), natrijev klorid, natrijev hidrogenfosfat heptahidrat, citratna kiselina hidrat i pročišćena voda.
English: • Itchy eyes
Croatian: • Suhoća oka
English: What you need to know before you use LUMIGAN 0.3 mg/ml
Croatian: Što morate znati prije nego počnete primjenjivati LUMIGAN 0,3 mg/ml
English: During 12 months' monotherapy treatment with LUMIGAN 0.3 mg/mL (multi-dose formulation) in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mmHg.
Croatian: Tijekom 12-mjesečne monoterapije s kapima LUMIGAN 0,3 mg/ml (višedozni pripravak) u odraslih bolesnika, u usporedbi s timololom, prosječna promjena u odnosu na početnu vrijednost u jutarnjem (08:00) intraokularnom tlaku kretala se u rasponu od -7,9 do -8,8 mmHg.
English: However, once the pouch is opened use within 30 days.
Croatian: Ipak, nakon otvaranja sadržaj vrećice iskoristite unutar 30 dana.
English: In addition to the adverse reactions seen with LUMIGAN 0.3 mg/mL single-dose, Table 3 lists additional adverse reactions that were seen with LUMIGAN 0.3 mg/mL (multi-dose formulation).
Croatian: Pored nuspojava zapaženih s otopinom jednodoznog LUMIGAN-a 0,3 mg/ml Tablica 3 navodi ostale nuspojave koje su zapažene s LUMIGAN-om 0,3 mg/ml (višedozni pripravak).
English: • Slight redness (up to 44% of people)
Croatian: • Lagano crvenilo (do 44% ljudi)
English: During 12 months' monotherapy treatment with LUMIGAN 0.3 mg/ml in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg.
Croatian: Tijekom 12-mjesečnog ispitivanja monoterapije s LUMIGAN-om 0,3 mg/ml u odraslih bolesnika, u usporedbi s timololom, prosječna promjena u odnosu na početnu vrijednost u jutarnjem (08:00) intraokularnom tlaku kretala se u rasponu od 7,9 do 8,8 mm Hg.
English: Skin and subcutaneous tissue disorders common pigmentation of periocular skin uncommon hirsutism not known skin discoloration (periocular)
Croatian: Poremećaji kože i potkožnog tkiva često pigmentacija kože oko oka manje često hirzutizam nepoznato diskoloracija kože (periokularno)
English: Sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water.
Croatian: Natrijev hidrogenfosfat heptahidrat, citratna kiselina hidrat, natrijev klorid, kloridna kiselina ili natrijev hidroksid (za podešavanje pH) i pročišćena voda.
English: Ocular use.
Croatian: Okularna primjena.
English: What LUMIGAN 0.3 mg/mL single-dose contains - The active substance is bimatoprost.
Croatian: Što jednodozni LUMIGAN 0,3 mg/ml sadrži - Djelatna tvar je bimatoprost.
English: What LUMIGAN 0.3 mg/ml is and what it is used for What you need to know before you use LUMIGAN 0.3 mg/ml How to use LUMIGAN 0.3 mg/ml Possible side effects
Croatian: Što je LUMIGAN 0,3 mg/ml i za što se koristi Što morate znati prije nego počnete primjenjivati LUMIGAN 0,3 mg/ml Kako primjenjivati LUMIGAN 0,3 mg/ml Moguće nuspojave
English: Limited experience is available in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.
Croatian: Kod bolesnika s glaukomom otvorenog kuta, s pseudoeksfolijativnim i pigmentarnim glaukomom te s kroničnim glaukomom zatvorenog kuta s prohodnom iridotomijom, iskustvo je ograničeno.
English: • Darker eyelid colour
Croatian: • Tamnija boja vjeđa
English: • Pain
Croatian: • Bol
English: LUMIGAN 0.3 mg/ml contains benzalkonium chloride Do not use the drops when you are wearing your lenses.
Croatian: LUMIGAN 0,3 mg/ml sadrži benzalkonijev klorid Nemojte primjenjivati kapi dok su Vam kontaktne leće u očima.
English: Co. Mayo
Croatian: Mayo
English: At 12 months, the incidence of iris hyperpigmentation with bimatoprost 0.1 mg/ml eye drops, solution was 0.5%.
Croatian: Nakon 12 mjeseci primjene bimatoprosta 0,1 mg/ml kapi za oko incidencija hiperpigmentacije šarenice bila je 0,5%.
English: Benzalkonium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water
Croatian: Benzalkonijev klorid, natrijev hidrogenfosfat heptahidrat, citratna kiselina hidrat, natrijev klorid, kloridna kiselina ili natrijev hidroksid (za podešavanje pH) i pročišćena voda.
English: If you forget to use LUMIGAN, use a single drop as soon as you remember, and then go back to your regular routine.
Croatian: Ako ste zaboravili primijeniti LUMIGAN 0,1 mg/ml Ako ste zaboravili primijeniti LUMIGAN, primijenite jednu kap čim se sjetite, a nakon toga se vratite uobičajenoj rutini.
English: • Tired eyes
Croatian: • Umorne oči
English: LUMIGAN 0.1 mg/ml contains benzalkonium chloride Do not use the drops when you are wearing your lenses.
Croatian: LUMIGAN 0,1 mg/ml sadrži benzalkonijev klorid Nemojte primjenjivati kapi dok su Vam kontaktne leće u očima.
English: - The other ingredients are sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water.
Croatian: - Drugi sastojci su natrijev klorid, natrijev hidrogenfosfat heptahidrat, citratna kiselina hidrat i pročišćena voda.
English: • Slight redness (up to 24% of people)
Croatian: • Lagano crvenilo (do 24% ljudi)
English: - Talk to your doctor, if: - You have any breathing problems - You have liver or kidney problems - You have had a cataract surgery in the past - You have dry eye - You have or have had any problems with your cornea (front transparent part of the eye) - You wear contact lenses (see “Important information about some of the ingredients of
Croatian: - Obavijestite svog liječnika ako: imate bilo kakvih problema s disanjem imate problema s jetrom ili bubrezima ste imali operaciju mrene u prošlosti imate suhe oči imate ili ste imali problema s rožnicom (prednji prozirni dio oka)
English: Eye disorders very common ocular pruritus, growth of eyelashes common asthenopia, conjunctival oedema, photophobia, tearing, increased iris pigmentation; blurred vision
Croatian: Poremećaji oka vrlo često svrbež oka, rast trepavica često astenopija, konjunktivalni edem, fotofobija, suzenje, pojačana pigmentacija šarenice; zamućen vid
English: Bimatoprost is a potent ocular hypotensive agent.
Croatian: Bimatoprost je snažna tvar za sniženje očnog tlaka.
English: A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: One ml of solution contains 0.3 mg bimatoprost.
Croatian: Jedan ml otopine sadrži 0,3 mg bimatoprosta.
English: There have been a limited number of spontaneous reports of bradycardia or hypotension with bimatoprost 0.3 mg/ml eye drops, solution.
Croatian: Bilo je nekoliko spontanih izvješća o bradikardiji ili hipotenziji s otopinom bimatoprost 0,3 mg/ml kapi za oko.
English: There have been rare spontaneous reports of reactivation of previous corneal infiltrates or ocular infections with bimatoprost 0.3 mg/mL eye drops, solution (multi-dose formulation).
Croatian: Bilo je nekoliko rijetkih spontanih izvješća o ponovnoj aktivaciji prethodnih rožničnih infiltrata ili očnih infekcija s otopinom bimatoprosta 0,3mg/ml kapi za oko (višedozni pripravak).
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.1 mg/ml eye drops, solution or in the post-marketing period.
Croatian: Sljedeće nuspojave prijavljene su tijekom kliničkih ispitivanja s LUMIGAN 0,1 mg/ml kapima za oko, ili nakon stavljanja lijeka na tržište.
English: • Skin redness around the eye
Croatian: • Crvenilo kože oko oka
English: Cystoid macular oedema has been uncommonly reported (≥1/1,000 to <1/100) following treatment with bimatoprost 0.3 mg/ml eye drops.
Croatian: Manje često je prijavljen cistoidni makularni edem (≥1/1000 do <1/100) nakon liječenja otopinom bimatoprost 0,3 mg/ml kapi za oko.
English: Nervous system disorders uncommon headache not known dizziness
Croatian: Poremećaji živčanog sustava manje često glavobolja nepoznato omaglica
English: There have been a limited number of spontaneous reports of bradycardia or hypotension with bimatoprost 0.3 mg/mL eye drops, solution (multi-dose formulation).
Croatian: Bilo je nekoliko spontanih izvješća o bradikardiji ili hipotenziji s otopinom bimatoprosta 0,3 mg/ml kapi za oko (višedozni pripravak).
English: In addition to the side effects for LUMIGAN 0.3 mg/mL single-dose, the following side effects have been seen with the preserved multi-dose formulation of LUMIGAN 0.3 mg/mL and may occur in patients taking LUMIGAN 0.3 mg/mL single-dose:
Croatian: Osim nuspojava primijećenih s primjenom kapi jednodoznog LUMIGAN-a 0,3 mg/ml, primijećene su nuspojave kod primjene kapi višedoznog pripravka LUMIGAN 0,3 mg/ml koji sadrži konzervans, a koje se mogu javiti i kod korisnika kapi jednodoznog LUMIGAN-a 0,3 mg/ml.
English: • Burning sensation in the eye
Croatian: • Osjećaj nelagode u oku
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/mL single-dose or in the post-marketing period.
Croatian: Sljedeće nuspojave prijavljene su tijekom kliničkih ispitivanja s otopinom jednodoznog LUMIGANa 0,3 mg/ml ili nakon stavljanja lijeka u promet.
English: After twice daily dosing with bimatoprost 0.3 mg/ml eye drops, solution, the mean AUC0-24hr value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults.
Croatian: Nakon što se otopina bimatoprost 0,3 mg/ml kapi za oko primijeni dvaput dnevno, srednja vrijednost AUC0-24h od 0,0634 ng•h/ml bimatoprosta kod starijih osoba (ispitanici od 65 godina ili stariji) bila je značajno viša u odnosu na 0,0218 ng•h/ml kod mladih i zdravih odraslih osoba.
English: Cystoid macular oedema has been uncommonly reported (≥1/1,000 to <1/100) following treatment with bimatoprost 0.3 mg/mL eye drops (multi-dose formulation).
Croatian: Manje često je prijavljen cistoidni makularni edem (≥1/1000 do <1/100) nakon liječenja otopinom bimatoprosta 0,3 mg/ml kapi za oko (višedoznog pripravka).
English: LUMIGAN 0.1 mg/ml, eye drops, solution Bimatoprost
Croatian: LUMIGAN 0,1 mg/ml, kapi za oko, otopina bimatoprost
English: After twice daily dosing of LUMIGAN 0.3 mg/mL, the mean AUC0-24hr value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults.
Croatian: Nakon što se otopina LUMIGAN 0,3 mg/ml primijeni dvaput dnevno, srednja vrijednost AUC0-24h od 0,0634 ng•h/ml bimatoprosta kod starijih osoba (ispitanici od 65 godina naviše) bila je značajno viša od 0,0218 ng•h/ml kod mladih i zdravih odraslih osoba.
English: Limited experience is available with the use of LUMIGAN in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.
Croatian: Kod bolesnika s glaukomom otvorenog kuta, s pseudoeksfolijativnim i pigmentarnim glaukomom te s kroničnim glaukomom zatvorenog kuta s prohodnom iridotomijom, iskustvo s primjenom kapi LUMIGAN je ograničeno.
English: One ml of solution contains 0.1 mg bimatoprost.
Croatian: Jedan ml otopine sadrži 0,1 mg bimatoprosta.
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/ml eye drops, solution or in the post-marketing period.
Croatian: Sljedeće nuspojave prijavljene su tijekom kliničkih ispitivanja s LUMIGAN 0,3 mg/ml kapima za oko, ili nakon stavljanja lijeka na tržište.
English: Cystoid macular oedema has been uncommonly reported (≥1/1,000 to <1/100) following treatment with bimatoprost 0.3 mg/ml eye drops, solution.
Croatian: Manje često je prijavljen cistoidni makularni edem (≥1/1000 do <1/100) nakon liječenja otopinom bimatoprosta 0,3 mg/ml kapi za oko.
English: Most were ocular, mild and none was serious.
Croatian: Većina njih se pojavila u očima; bile su blage, a nijedna ozbiljne prirode.
English: At 12 months, the incidence of iris pigmentation with bimatoprost 0.3 mg/mL (multi-dose formulation) was 1.5% (see section 4.8) and did not increase following 3 years treatment.
Croatian: Nakon 12 mjeseci primjene bimatoprosta 0,3 mg/ml (višedozni pripravak) incidencija hiperpigmentacije šarenice bila je 1,5% (vidjeti dio 4.8) i nije se povećavala iduće 3 godine.
English: Detailed information on this medicinal product is available on the European Medicines Agency web site: http://www.ema.europa.eu/
Croatian: Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu
English: At 12 months, the incidence with bimatoprost 0.3 mg/ml eye drops, solution was 1.5% (see section 4.8 Table 2) and did not increase following 3 years treatment.
Croatian: Nakon 12 mjeseci primjene bimatoprosta 0,3 mg/ml kapi za oko incidencija hiperpigmentacije šarenice bila je 1,5% (vidjeti dio 4.8, tablica 2) i nije se povećavala iduće 3 godine liječenja.
English: Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
Croatian: Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
English: Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing.
Croatian: Nakon okularne primjene kada dosegne sistemsku cirkulaciju, bimatoprost je glavna tvar koja cirkulira tijelom.
English: Concomitant use of LUMIGAN and antiglaucomatous agents other than topical beta-blockers has not been evaluated during adjunctive glaucoma therapy.
Croatian: Tijekom kombiniranog liječenja glaukoma nije ispitana istovremena primjena kapi LUMIGAN i tvari koje se koriste u liječenju glaukoma a koje su drukčije od topikalnih beta-blokatora.
English: • Swelling of the surface of the eye
Croatian: • Otečena površina oka
English: If you use more LUMIGAN 0.3 mg/ml than you should If you use more LUMIGAN than you should, it is unlikely to cause you any serious harm.
Croatian: Ako primijenite više LUMIGAN-a nego što ste trebali, nije vjerojatno da će Vam ozbiljno naštetiti.
English: Allergan Pharmaceuticals Ireland
Croatian: NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Allergan Pharmaceuticals Ireland
English: Table 3
Croatian: Tablica 3.
English: What LUMIGAN 0.3 mg/mL single-dose is and what it is used for What you need to know before you use LUMIGAN 0.3 mg/mL single-dose How to use LUMIGAN 0.3 mg/mL single-dose Possible side effects
Croatian: Što je jednodozni LUMIGAN 0,3 mg/ml i za što se koristi Što morate znati prije nego počnete primjenjivati jednodozni LUMIGAN 0,3 mg/ml Kako primjenjivati jednodozni LUMIGAN 0,3 mg/ml Moguće nuspojave
English: • Inflamed eyelids
Croatian: • Upaljene očne vjeđe
English: LUMIGAN 0.3 mg/ml, eye drops, solution Bimatoprost
Croatian: LUMIGAN 0,3 mg/ml, kapi za oko, otopina bimatoprost
English: Nervous system disorders common headache uncommon dizziness
Croatian: Poremećaji živčanog sustava često glavobolja manje često omaglica
English: Tel: +385 1 6646 563
Croatian: Ewopharma d.o.o. Tel: +385 1 6646 563
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA JEDNU BOČICU
English: Talk to your doctor or pharmacist before you use LUMIGAN 0.1 mg/ml Talk to your doctor, if: - You have any breathing problems - You have liver or kidney problems - You have had a cataract surgery in the past - You have dry eye - You have or have had any problems with your cornea (front transparent part of the eye) - You wear contact lenses (see “Important information about some of the ingredients of
Croatian: Obavijestite svog liječnika ako: imate bilo kakvih problema s disanjem imate problema s jetrom ili bubrezima ste imali operaciju mrene u prošlosti imate suhe oči imate ili ste imali problema s rožnicom (prednji prozirni dio oka)
English: LUMIGAN 0.1 mg/ml is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Croatian: Preosjetljivosti na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1. LUMIGAN 0,1 mg/ml je kontraindiciran kod bolesnika koji su u prošlosti imali suspektnu nuspojavu na benzalkonijev klorid, koja je dovela do prekida terapije.
English: Reporting side effects
Croatian: Prijavljivanje nuspojava
English: If you use more LUMIGAN 0.3 mg/mL single-dose than you should If you use more of this medicine than you should, it is unlikely to cause you any serious harm.
Croatian: Ako primijenite više lijeka nego što ste trebali, nije vjerojatno da će Vam ozbiljno naštetiti.
English: At 12 months, the incidence of iris pigmentation with bimatoprost 0.3mg/ml was 1.5% (see section 4.8) and did not increase following 3 years treatment.
Croatian: Nakon 12 mjeseci primjene bimatoprostom 0,3 mg/ml kapi za oko incidencija hiperpigmentacije šarenice bila je 1,5% (vidjeti dio 4.8) i nije se povećavala iduće 3 godine.
English: Respiratory
Croatian: Dišni sustav
English: Tel: +48 22 256 37 00
Croatian: Allergan Sp. z o.o. Tel: +48 22 256 37 00
English: Eye drops, solution 90 x 0.4 ml
Croatian: 90 x 0,4 ml
English: Immune system disorders not known
Croatian: Nuspojave nepoznate učestalosti
English: In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml.
Croatian: U kliničkim ispitivanjima, s LUMIGAN 0,3 mg/ml višedoznim pripravkom liječeno je više od 1800 bolesnika.
English: EU/1/02/205/005-007
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/02/205/005-007